Involvement of dopamine (DA)/serotonin (5-HT)/sigma (σ) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist

Brain Research Bulletin

Volumn 74, Issue 1-3, 2007, Pages 58-65

  Dhir, Ashish ^a   Kulkarni, S K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Dopaminergic modulation; Forced swim test (FST); Ropinirole; Serotonergic modulation; Sigma receptors; Tail suspension test (TST)

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; ETHYLENEDIAMINE DERIVATIVE; HALOPERIDOL; N [2 (2,3 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; PROGESTERONE; RIMCAZOLE; ROPINIROLE; SEROTONIN; SIGMA OPIATE RECEPTOR; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG MECHANISM; ELECTROCHEMICAL DETECTION; EXPERIMENTAL TEST; FORCED SWIMMING TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMOBILIZATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL SUSPENSION TEST; TISSUE LEVEL;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROCHEMISTRY; HINDLIMB SUSPENSION; INDOLES; MALE; MICE; MOTOR ACTIVITY; RECEPTORS, SIGMA; SEROTONIN; SWIMMING;

EID: 34547544206     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2007.05.004     Document Type: Article

References (69)

1. Ainsworth K., Smith S.E., Zetterstrom T.S., Pei Q., Franklin M., and Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl.) 140 (1998) 470-477
2. Basso A.M., Gallagher K.B., Bratcher N.A., Brioni J.D., Moreland R.B., Hsieh G.C., Drescher K., Fox G.B., Decker M.W., and Rueter L.E. Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology 30 (2005) 1257-1268
3. Bermack J.E., and Debonnel G. The role of sigma receptors in depression. J. Pharmacol. Sci. 97 (2005) 317-336
4. Berton O., and Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Neurosci. 7 (2006) 137-151
5. Beyer C.E., Boikess S., Luo B., and Dawson L.A. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J. Psychopharmacol. 16 (2002) 297-304
6. 1B agonists: involvement of the hippocampo-accumbens pathways. Neuropharmacology 35 (1996) 1521-1529
7. Cassano P., Lattanzi L., Fava M., Navari S., Battistini G., Abelli M., and Cassano G.B. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can. J. Psychiatry 50 (2005) 357-360
8. Chen J., Paredes W., Van Praag H.M., Lowinson J.H., and Gardner E.L. Presynaptic dopamine release is enhanced by 5-HT3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse 10 (1992) 264-266
9. D'Aquila P.S., Collu M., Gessa G.L., and Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur. J. Pharmacol. 405 (2000) 365-373
10. Dhir A., Naidu P.S., and Kulkarni S.K. Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes. Addict. Biol. 10 (2005) 329-335
11. A. Dhir, S.K. Kulkarni, Involvement of sigma-1 receptor modulation in the antidepressant action of venlafaxine. Neurosci. Lett., in press.
12. A. Dhir, S.K. Kulkarni, Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur. J. Pharmacol., in press.
13. A. Dhir, S.K. Kulkarni, Possible involvement of l-Arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride. Eur. J. Pharmacol., in press.
14. Diaz-Torga G., Feierstein C., Libertun C., Gelman D., Kelly M.A., Low M.J., Rubinstein M., and Becu-Villalobos D. Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice. Endocrinology 143 (2002) 1270-1279
15. Duterte-Boucher D., Leclere J.F., Panissaud C., and Costentin J. Acute effects of direct dopamine agonists in the mouse behavioral despair test. Eur. J. Pharmacol. 13 (1988) 185-190
16. Ebert D., and Lammers C.H. The central dopaminergic system and depression. Nervenarzt 68 (1997) 545-555
17. Ferre S., and Artigas F. Dopamine D2 receptor-mediated regulation of serotonin extracellular concentration in the dorsal raphe nucleus of freely moving rats. J. Neurochem. 61 (1993) 772-776
18. Ferre S., Cortes R., and Artigas F. Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J. Neurosci. 14 (1994) 4839-4846
19. Hashimoto K., Fujita Y., and Iyo M. Phencyclidine-induced Cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: Role of sigma-1 receptors. Neuropsychopharmacology 32 (2007) 514-521
20. Hashimoto K., and Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr. Pharm. Des. 12 (2006) 3857-3876
21. Hayashi T., and Su T.P. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18 (2004) 269-284
22. Ishihara K., and Sasa M. Modulation of neuronal activities in the central nervous system via sigma receptors. Nihon Shinkei Seishin Yakurigaku Zasshi 22 (2002) 23-30
23. Jacobs B.L., and Azmitia E.C. Structure and function of the brain serotonin system. Physiol. Rev. 72 (1992) 165-229
24. Joca S.R., Skalisz L.L., Beijamini V., Vital M.A., and Andreatini R. The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. Eur. Neuropsychopharmacol. 10 (2000) 223-228
25. Jost W.H., and Angersbach D. Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev. 11 (2005) 253-272
26. Kapur S., and Mann J.J. Role of the dopaminergic system in depression. Biol. Psychiatry 32 (1992) 1-17
27. Kobayashi T., Matsuno K., Murai M., and Mita S. Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain. Neurochem. Res. 22 (1997) 1105-1109
28. Kulkarni S.K., and Mehta A.K. Purine nucleoside-mediated immobility in mice: reversal by antidepressants. Psychopharmacology 85 (1985) 460-463
29. Kvernmo T., Hartter S., and Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin. Ther. 28 (2006) 1065-1078
30. Lambert G., Johansson M., Agren H., and Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch. Gen. Psychiatry 57 (2000) 787-793
31. Lee E.H., and Geyer M.A. Indirect effects of apomorphine on serotoninergic neurons in rats. Neuroscience 11 (1984) 437-442
32. Lee E.H., Wang F.B., Tang Y.P., and Geyer M.A. Gabaergic interactions in the dorsal raphe mediate the effects of apomorphine on serotonergic system. Brain Res. Bull. 18 (1987) 345-353
33. Lehr E. Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice. Psychopharmacology (Berl.) 163 (2002) 495-500
34. Lemke M.R. Antidepressant effects of dopamine agonists: experimental and clinical findings. Nervenarzt 23 (2006) [Epub ahead of print]
35. Maj J., and Rogoz Z. Synergistic effect of pramipexole and sertraline in the forced swimming test. Pol. J. Pharmacol. 51 (1999) 471-475
36. Maj J., Rogoz Z., Skuza G., and Kolodziejczyk K. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J. Neural. Transm. 104 (1997) 525-533
37. Mantovani M., Bubl B., and Feuerstein T.J. 5-HT uptake blockade prevents the increasing effect of K(ATP) channel blockers on electrically evoked [3H]-5-HT release in rat and mouse neocortical slices. Neurochem. Int. 48 (2006) 218-225
38. Mendlin A., Martin F.J., and Jacobs B.L. Dopaminergic input is required for increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in rat forebrain. Neuroscience 93 (1999) 897-905
39. Narita N., Hashimoto K., Tomitaka S., and Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur. J. Pharmacol. 307 (1996) 117-119
40. Nordin C., Siwers B., and Bertilsson L. Bromocriptine treatment of depressive disorders. Clinical and biochemical effects. Acta Psychiatr. Scand. 64 (1981) 25-33
41. Okuyama S. Atypical antipsychotic profiles of sigma receptor ligands. Nippon Yakurigaku Zasshi 114 (1999) 13-23
42. Parale M.P., and Kulkarni S.K. Clonidine-induced behavioural despair in mice: reversal by antidepressants. Psychopharmacology 89 (1986) 171-174
43. Parsons L.H., and Justice J.B. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens of the rat as measured by in vivo microdialysis. Brain Res. 606 (1993) 195-199
44. 1B receptor stimulation enhances dopamine-mediated reinforcement. Psychopharmacology 128 (1996) 150-160
45. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47 (1978) 379-391
46. Porsolt R.D., Bertin A., and Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229 (1977) 327-336
47. Porsolt R.D., Bertin A., and Jalfre M. "Behavioural despair" in rats and mice: strain differences and the effects of imipramine. Eur. J. Pharmacol. 51 (1978) 291-294
48. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
49. Randrup A., Munkvad I., Fog R., Gerlach J., Molander L., Kjellberg B., and Scheel-Kruger J. Mania, depression and brain dopamine. In: Essman W.B., and Valzelli L. (Eds). Current Developments in Psychopharmacology vol. 2 (1975), Spectrum Publications, New York 206-248
50. Ravikumar K., and Sridhar B. Ropinirole hydrochloride, a dopamine agonist. Acta Crystallogr. C 62 (2006) 265-267
51. Reddy D.S., Kaur G., and Kulkarni S.K. Sigma (sigma 1) receptor mediated anti-depressant-like effects of neurosteroids in the Porsolt forced swim test. Neuroreport 9 (1998) 3069-3073
52. Rogers D.C., Costall B., Domeney A.M., Gerrard P.A., Greener M., Kelly M.E., Hagan J.J., and Hunter A.J. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset. Psychopharmacology (Berl) 151 (2000) 91-97
53. Rogoz Z., and Skuza G. Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacol. Rep. 58 (2006) 493-500
54. Rogoz Z., Skuza G., Kusmider M., Wojcikowski J., Kot M., and Daniel W.A. Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol. J. Pharmacol. 56 (2004) 179-185
55. Sandyk R. Serotonin in involuntary movement disorders. Int. J. Neurosci. 42 (1988) 185-205
56. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 122 (1965) 509-522
57. Sekine Y., Suzuki K., Ramachandran P.V., Blackburn T.P., and Ashby C.R. Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 61 (2007) 72-77
58. 3. Psychopharmacology 175 (2004) 163-169
59. Stahl S.M. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 10 (2005) 319-323
60. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85 (1985) 367-370
61. Su T., and Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr. Med. Chem. 10 (2003) 2073-2080
62. Takebayashi M., Hayashi T., and Su T.P. A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. Pharmacopsychiatry 37 (2004) S208-S213
63. Traskman L., Asberg M., Bertilsson L., and Sjostrand L. Monoamine metabolites in CSF and suicidal behavior. Arch. Gen. Psychiatry 38 (1981) 631-636
64. Tremblay L.K., Naranjo C.A., Cardenas L., Herrmann N., and Busto U.E. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch. Gen. Psychiatry 59 (2002) 409-416
65. West A.R., and Galloway M.P. Regulation of serotonin facilitated dopamine release in in vivo: the role of protein kinase A activating transduction mechanism. Synapse 23 (1991) 20-27
66. Willner P. Animal models of depression: validity and applications. Adv. Biochem. Psychopharmacol. 49 (1995) 19-41
67. Willner P., Hale A.S., and Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J. Affect. Disord. 86 (2005) 37-45
68. Yagasaki Y., Numakawa T., Kumamaru E., Hayashi T., Su T.P., and Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J. Biol. Chem. 281 (2006) 12941-12949
69. Yamada J., Sugimoto Y., and Yamada S. Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur. J. Pharmacol. 504 (2004) 207-211